Alibaba Health Information Technology Ltd

Chart & Performance

D1W1MN

P/E

58.29

P/S

1.91

EPS

0.05

Div Yield, %

0.00%

Shrs. gr., 5y

4.97%

Rev. gr., 5y

39.61%

Revenues

27.03b

+0.98%

Net income

883m

+64.93%

CFO

1.08b

+322.32%

Dividend

Jan 21, 19987 HKD/sh

Profile

Alibaba Health Information Technology Limited, an investment holding company, engages in the pharmaceutical direct sales, pharmaceutical e-commerce platform, and healthcare and digital services businesses in Mainland China and Hong Kong. It offers range of prescription drugs, over-the-counter drugs, nutritional supplements, medical devices, contact lenses, and various other health-related products through its online stores on Tmall.com and offline pharmacy outlets to business-to-customer and business-to-business customers; and pharmaceutical products, medical devices and healthcare products, health food, sexual health and family planning products, contact lenses, and medical and healthcare services through its e-commerce platform. The company also provides medical and healthcare services, including medical checkups, nucleic acid testing, medical consultation, registration, vaccination, and TCM through various channels, such as Taobao, Tmall, Alipay, Dr. Deer APP, Gaode, DingTalk, and Quark. In addition, it engages in the tracking business; provision of network hospital, healthcare related internet information, internet information, and healthcare related technical services; operation of internet hospitals; and asset management services. The company was formerly known as CITIC 21CN Company Limited and changed its name to Alibaba Health Information Technology Limited in September 2014. Alibaba Health Information Technology Limited is based in Causeway Bay, Hong Kong.

URL

https://www.alihealth.cn/

IPO date

Jul 06, 1972

Employees

1,560

Domiciled in

Incorporated in

Valuation

Order:

Title CNY in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title CNY in thousands, except ratios and share amounts	2024‑03	2023‑03	2022‑03	2021‑03	2020‑03	2019‑03	2018‑03	2017‑03	2016‑03	2015‑03
Income
Revenues	27,026,555 0.98%	26,763,016 30.06%	20,577,616 32.60%
Cost of revenue	23,973,160	23,887,666	19,574,812
Unusual Expense (Income)
NOPBT	3,053,395	2,875,350	1,002,804
NOPBT Margin	11.30%	10.74%	4.87%
Operating Taxes	56,263	16,731	13,427
Tax Rate	1.84%	0.58%	1.34%
NOPAT	2,997,132	2,858,619	989,377
Net income	883,477 64.93%	535,653 -301.71%	(265,555) -176.18%
Dividends
Dividend yield
Proceeds from repurchase of equity	(103,690)	(68,692)	(6,826)
BB yield	0.23%	0.09%	0.01%
Debt
Debt current	34,194	37,437	50,656
Long-term debt	130,146	118,159	220,172
Deferred revenue		(122,417)
Other long-term liabilities		122,417	106,363
Net debt	(14,288,843)	(15,353,074)	(14,573,630)
Cash flow
Cash from operating activities	1,079,832	255,690	424,363
CAPEX	(22,774)	(5,612)	(14,930)
Cash from investing activities	(4,880,900)	(532,436)	1,872,308
Cash from financing activities	(1,982,395)	(111,278)	(58,628)
FCF	2,962,013	2,955,177	876,560
Balance
Cash	9,553,110	10,917,171	10,547,851
Long term investments	4,900,073	4,591,499	4,296,607
Excess cash	13,101,855	14,170,519	13,815,577
Stockholders' equity	104,201	(748,932)	(1,216,098)
Invested Capital	14,495,573	15,910,527	15,489,281
ROIC	19.71%	18.21%	6.46%
ROCE	20.75%	18.81%	6.97%
EV
Common stock shares outstanding	14,090,693	13,541,580	13,482,634
Price	3.18 -44.01%	5.68 11.81%	5.08 -76.91%
Market cap	44,808,403 -41.74%	76,916,172 12.30%	68,491,781 -76.64%
EV	30,492,952	89,304,053	82,080,015
EBITDA	3,107,077	2,939,069	1,063,380
EV/EBITDA	9.81	30.39	77.19
Interest	5,969	5,833	3,815
Interest/NOPBT	0.20%	0.20%	0.38%